| 1 |
Celani LMS, Egito EST, Azevedo ÍM, Oliveira CN, Dourado D, Medeiros AC. Treatment of colitis by oral negatively charged nanostructured curcumin in rats. Acta Cir Bras 2022;37:e370602. [PMID: 35976279 DOI: 10.1590/acb370602] [Reference Citation Analysis]
|
| 2 |
Janker L, Schuster D, Bortel P, Hagn G, Brunmair J, Meier-menches SM, Mader JC, Slany A, Bileck A, Madl C, Unger L, Hennlich B, Weitmayr B, Del Favero G, Pils D, Pukrop T, Pfisterer N, Feichtenschlager T, Gerner C. Multi-omics empowered deep phenotyping of ulcerative colitis.. [DOI: 10.1101/2022.05.25.22275502] [Reference Citation Analysis]
|
| 3 |
Fukuchi T, Kawashima K, Koga H, Utsunomiya R, Sugiyama K, Shimazu K, Eguchi T, Ishihara S. Induction of mucosal healing by intensive granulocyte/monocyte adsorptive apheresis (GMA) without use of corticosteroids in patients with ulcerative colitis: long-term remission maintenance after induction by GMA and efficacy of GMA re-treatment upon relapse. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Yin J, Wei L, Wang N, Li X, Miao M. Efficacy and safety of adjuvant curcumin therapy in ulcerative colitis: A systematic review and meta-analysis. Journal of Ethnopharmacology 2022. [DOI: 10.1016/j.jep.2022.115041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Bao WL, Wu Q, Hu B, Sun D, Zhao S, Shen X, Cheng H, Shen W. Oral Nanoparticles of SNX10-shRNA Plasmids Ameliorate Mouse Colitis. Int J Nanomedicine 2021;16:345-57. [PMID: 33488076 DOI: 10.2147/IJN.S286392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 6 |
Li N, Mao J, Tang H, Zhu L, Tan X, Bi J, Wu H, Chen X, Wang Y. Efficacy and safety of adsorptive granulomonocytapheresis in Chinese patients with ulcerative colitis: A retrospective analysis of 50 cases with focus on factors impacting clinical efficacy. J Clin Apher 2020;35:271-80. [PMID: 32378240 DOI: 10.1002/jca.21787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 7 |
Zheng T, Wang X, Chen Z, He A, Zheng Z, Liu G. Efficacy of adjuvant curcumin therapy in ulcerative colitis: A meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2020;35:722-9. [PMID: 31696975 DOI: 10.1111/jgh.14911] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 8 |
Regmi S, Pathak S, Nepal MR, Shrestha P, Park J, Kim JO, Yong CS, Choi D, Chang J, Jeong TC, Orive G, Yook S, Jeong J. Inflammation-triggered local drug release ameliorates colitis by inhibiting dendritic cell migration and Th1/Th17 differentiation. Journal of Controlled Release 2019;316:138-49. [DOI: 10.1016/j.jconrel.2019.11.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 9 |
Han W, Xie B, Li Y, Shi L, Wan J, Chen X, Wang H. Orally Deliverable Nanotherapeutics for the Synergistic Treatment of Colitis-Associated Colorectal Cancer. Theranostics 2019;9:7458-73. [PMID: 31695780 DOI: 10.7150/thno.38081] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 10 |
Li C, Zhao Y, Cheng J, Guo J, Zhang Q, Zhang X, Ren J, Wang F, Huang J, Hu H, Wang R, Zhang J. A Proresolving Peptide Nanotherapy for Site-Specific Treatment of Inflammatory Bowel Disease by Regulating Proinflammatory Microenvironment and Gut Microbiota. Adv Sci (Weinh) 2019;6:1900610. [PMID: 31559126 DOI: 10.1002/advs.201900610] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 20.3] [Reference Citation Analysis]
|
| 11 |
Nishida Y, Hosomi S, Watanabe K, Watanabe K, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Yamagami H, Tanigawa T, Watanabe T, Fujiwara Y. Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis. Scand J Gastroenterol 2018;53:579-85. [PMID: 29171305 DOI: 10.1080/00365521.2017.1403647] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 12 |
Mohammed Vashist N, Samaan M, Mosli MH, Parker CE, MacDonald JK, Nelson SA, Zou GY, Feagan BG, Khanna R, Jairath V. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev 2018;1:CD011450. [PMID: 29338066 DOI: 10.1002/14651858.CD011450.pub2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 53] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 13 |
Fukuda T, Naganuma M, Sugimoto S, Nanki K, Mizuno S, Mutaguchi M, Nakazato Y, Inoue N, Ogata H, Iwao Y, Kanai T. The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry. PLoS One 2017;12:e0187737. [PMID: 29108025 DOI: 10.1371/journal.pone.0187737] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 14 |
Shimazu K, Fukuchi T, Kim I, Noguchi Y, Iwata M, Koyama S, Ubukata S, Tanaka A. Efficacy and Usefulness of New Single-Needle Intensive Granulocyte and Monocyte Adsorptive Apheresis in Active Ulcerative Colitis Patients Without Corticosteroids and Biologics. Ther Apher Dial. 2016;20:383-389. [PMID: 27523079 DOI: 10.1111/1744-9987.12470] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 15 |
Nishida Y, Hosomi S, Yamagami H, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Tanigawa T, Shiba M, Watanabe K, Watanabe T, Tominaga K, Fujiwara Y. Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis. PLoS One. 2017;12:e0169845. [PMID: 28076386 DOI: 10.1371/journal.pone.0169845] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 16 |
Kanai T. Leukocytapheresis Therapy of Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_49] [Reference Citation Analysis]
|
| 17 |
Vong LB, Nagasaki Y. Development of Redox Nanomedicine for Gastrointestinal Complications via Oral Administration Route. ACS Symposium Series 2017. [DOI: 10.1021/bk-2017-1253.ch002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 18 |
Casili G, Cordaro M, Impellizzeri D, Bruschetta G, Paterniti I, Cuzzocrea S, Esposito E. Dimethyl Fumarate Reduces Inflammatory Responses in Experimental Colitis. J Crohns Colitis 2016;10:472-83. [PMID: 26690241 DOI: 10.1093/ecco-jcc/jjv231] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 19 |
Komaki Y, Komaki F, Sakuraba A, Cohen R. Approach to Optimize Anti-TNF-α Therapy in Patients With IBD. Curr Treat Options Gastroenterol. 2016;14:83-90. [PMID: 26872815 DOI: 10.1007/s11938-016-0079-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 20 |
Hanauer SB, Podolsky DK. Ulcerative Colitis. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch71] [Reference Citation Analysis]
|
| 21 |
Li Q, Zhai W, Jiang Q, Huang R, Liu L, Dai J, Gong W, Du S, Wu Q. Curcumin-piperine mixtures in self-microemulsifying drug delivery system for ulcerative colitis therapy. Int J Pharm 2015;490:22-31. [PMID: 25957703 DOI: 10.1016/j.ijpharm.2015.05.008] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 22 |
Song Y, Zheng P. Efficacy and safety of tumor necrosis factor-α blockers for ulcerative colitis: A systematic review and meta-analysis of published randomized controlled trials. Journal of Food and Drug Analysis 2015;23:1-10. [DOI: 10.1016/j.jfda.2014.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 23 |
Sacco R, Tanaka T, Yamamoto T, Bresci G, Saniabadi AR. Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders. Expert Rev Gastroenterol Hepatol 2015;9:327-33. [PMID: 25160857 DOI: 10.1586/17474124.2014.953060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 24 |
Mosli M, Samaan M, Nelson SA, Feagan BG, Travis S, D'haens G, Sandborn WJ, Zou G, Macdonald JK, Levesque BG. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database of Systematic Reviews 2015. [DOI: 10.1002/14651858.cd011450] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 25 |
Chhaya V, Saxena S, Cecil E, Chatu S, Subramanian V, Curcin V, Majeed A, Pollok RC. The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989-2009. Aliment Pharmacol Ther 2015;41:87-98. [PMID: 25382737 DOI: 10.1111/apt.13017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 26 |
Kim JW, Kim HJ, Lee CK, Shim JJ, Jang JY, Dong SH, Kim BH, Chang YW, Chi SG. Elevation of PRKCDBP, a novel transcriptional target of TNF-α, and its downregulation by infliximab in patients with ulcerative colitis. Dig Dis Sci 2014;59:2947-57. [PMID: 25052149 DOI: 10.1007/s10620-014-3282-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 27 |
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 28 |
Yoshitomi T, Nagasaki Y. Reactive oxygen species-scavenging nanomedicines for the treatment of oxidative stress injuries. Adv Healthc Mater 2014;3:1149-61. [PMID: 24482427 DOI: 10.1002/adhm.201300576] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 29 |
Dong Y, Zhou Z, Ding H, Zhang S. Preparation and properties of a pH sensitive carrier based on three kinds of polymer blend to control the release of 5-amino salicylic acid. Pharm Dev Technol 2014;19:960-7. [PMID: 24320757 DOI: 10.3109/10837450.2013.846372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 30 |
Vong LB, Yoshitomi T, Morikawa K, Saito S, Matsui H, Nagasaki Y. Oral nanotherapeutics: effect of redox nanoparticle on microflora in mice with dextran sodium sulfate-induced colitis. J Gastroenterol 2014;49:806-13. [PMID: 23715850 DOI: 10.1007/s00535-013-0836-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 31 |
Mosli MH, Feagan BG, Sandborn WJ, Dʼhaens G, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, Macdonald JK, Vandervoort MK, Geboes K, Levesque BG. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis 2014;20:564-75. [PMID: 24412993 DOI: 10.1097/01.MIB.0000437986.00190.71] [Cited by in Crossref: 89] [Cited by in F6Publishing: 76] [Article Influence: 9.9] [Reference Citation Analysis]
|
| 32 |
Mir SA, Nagy-Szakal D, Smith EO, Gilger MA, Kellermayer R. Duration of disease may predict response to infliximab in pediatric ulcerative colitis. J Clin Gastroenterol 2014;48:248-52. [PMID: 24129407 DOI: 10.1097/MCG.0b013e31829f2e06] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 33 |
Li J, Chen C, Cao XN, Wang GH, Hu JB, Wang J. Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats. J Huazhong Univ Sci Technolog Med Sci 2014;34:59-65. [PMID: 24496680 DOI: 10.1007/s11596-014-1232-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 34 |
Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S, Rutgeerts P. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400.e3. [PMID: 24512909 DOI: 10.1053/j.gastro.2013.10.052] [Cited by in Crossref: 614] [Cited by in F6Publishing: 632] [Article Influence: 68.2] [Reference Citation Analysis]
|
| 35 |
Ferrante M, Vermeire S, Van Assche G, Rutgeerts P. Infliximab for Ulcerative Colitis. Medical Therapy of Ulcerative Colitis 2014. [DOI: 10.1007/978-1-4939-1677-1_15] [Reference Citation Analysis]
|
| 36 |
Chhaya V, Pollok R. The impact of thiopurines on surgical outcomes in inflammatory bowel disease: do they make a difference? F1000Prime Rep 2013;5:50. [PMID: 24273651 DOI: 10.12703/P5-50] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 37 |
Dahlén R, Strid H, Lundgren A, Isaksson S, Raghavan S, Magnusson MK, Simrén M, Sjövall H, Öhman L. Infliximab inhibits activation and effector functions of peripheral blood T cells in vitro from patients with clinically active ulcerative colitis. Scand J Immunol. 2013;78:275-284. [PMID: 23713660 DOI: 10.1111/sji.12081] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 38 |
Naganuma M, Sakuraba A, Hibi T. Ulcerative colitis: prevention of relapse. Expert Rev Gastroenterol Hepatol 2013;7:341-51. [PMID: 23639092 DOI: 10.1586/egh.13.18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 39 |
Flourié B, Hagège H, Tucat G, Maetz D, Hébuterne X, Kuyvenhoven JP, Tan TG, Pierik MJ, Masclee AA, Dewit O, Probert CS, Aoucheta D; MOTUS study investigators. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther 2013;37:767-75. [PMID: 23451806 DOI: 10.1111/apt.12266] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 40 |
Tominaga K, Nakano M, Hoshino M, Kanke K, Hiraishi H. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. BMC Gastroenterol. 2013;13:41. [PMID: 23452668 DOI: 10.1186/1471-230x-13-41] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 41 |
Aust DE. Chronisch-entzündliche Erkrankungen des Kolorektums. Pathologie 2013. [DOI: 10.1007/978-3-642-02322-4_27] [Reference Citation Analysis]
|
| 42 |
Mosli MH, Feagan BG. The emerging role of vedolizumab in the treatment of ulcerative colitis. Clinical Investigation 2012;2:1201-1212. [DOI: 10.4155/cli.12.119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 43 |
Vong LB, Tomita T, Yoshitomi T, Matsui H, Nagasaki Y. An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice. Gastroenterology 2012;143:1027-36.e3. [PMID: 22771506 DOI: 10.1053/j.gastro.2012.06.043] [Cited by in Crossref: 139] [Cited by in F6Publishing: 141] [Article Influence: 12.6] [Reference Citation Analysis]
|
| 44 |
Biondi A, Zoccali M, Costa S, Troci A, Contessini-Avesani E, Fichera A. Surgical treatment of ulcerative colitis in the biologic therapy era. World J Gastroenterol 2012; 18(16): 1861-1870 [PMID: 22563165 DOI: 10.3748/wjg.v18.i16.1861] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 45 |
Dulger AC, Begenik H, Demirtas L, Esen R, Emre H. A Flare of Ulcerative Colitis Accompanied With Cerebral Sinus Venous Thrombosis And Bilateral Thalamic Infarctus: A Case Report. Gastroenterology Res 2012;5:67-70. [PMID: 27785183 DOI: 10.4021/gr403w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 46 |
Reiser M, Heringlake S, Henke H, Schmiegel W, Brechmann T. Krankheiten des Magen-Darm-Traktes und der Bauchspeicheldrüse. Die ärztliche Begutachtung 2012. [DOI: 10.1007/978-3-642-21081-5_13] [Reference Citation Analysis]
|
| 47 |
Yoshimura N, Tadami T, Kawaguchi T, Sako M, Yoshimoto H, Yamaka T, Takazoe M. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes. J Gastroenterol 2012;47:49-55. [PMID: 21915624 DOI: 10.1007/s00535-011-0464-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 48 |
Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2011. [DOI: 10.1002/14651858.cd007443.pub2] [Cited by in Crossref: 60] [Cited by in F6Publishing: 76] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 49 |
Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201. [PMID: 21723220 DOI: 10.1053/j.gastro.2011.06.054] [Cited by in Crossref: 643] [Cited by in F6Publishing: 672] [Article Influence: 53.6] [Reference Citation Analysis]
|
| 50 |
Hoentjen F, Sakuraba A, Hanauer S. Update on the Management of Ulcerative Colitis. Curr Gastroenterol Rep 2011;13:475-85. [DOI: 10.1007/s11894-011-0216-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 51 |
Osman MM, Lulic D, Glover L, Stahl CE, Lau T, van Loveren H, Borlongan CV. Cyclosporine-A as a neuroprotective agent against stroke: its translation from laboratory research to clinical application. Neuropeptides. 2011;45:359-368. [PMID: 21592568 DOI: 10.1016/j.npep.2011.04.002] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 52 |
Bautzová T, Rabišková M, Lamprecht A. Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease. Drug Development and Industrial Pharmacy 2011;37:1100-9. [DOI: 10.3109/03639045.2011.560156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 53 |
Mack DR. Probiotics in inflammatory bowel diseases and associated conditions. Nutrients. 2011;3:245-264. [PMID: 22254095 DOI: 10.3390/nu3020245] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 54 |
Andus T, Kocjan A, Müser M, Baranovsky A, Mikhailova TL, Zvyagintseva TD, Dorofeyev AE, Lozynskyy YS, Cascorbi I, Stolte M, Vieth M, Dilger K, Mohrbacher R, Greinwald R; International Salofalk Suppository OD Study Group. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis 2010;16:1947-56. [PMID: 20310020 DOI: 10.1002/ibd.21258] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 55 |
Lindberg A, Eberhardson M, Karlsson M, Karlén P. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol. 2010;10:73. [PMID: 20604939 DOI: 10.1186/1471-230x-10-73] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 56 |
Romano C, Famiani A, Comito D, Rossi P, Raffa V, Fries W. Oral beclomethasone dipropionate in pediatric active ulcerative colitis: a comparison trial with mesalazine. J Pediatr Gastroenterol Nutr 2010;50:385-9. [PMID: 20179636 DOI: 10.1097/MPG.0b013e3181bb3457] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 57 |
Kostadinova FI, Baba T, Ishida Y, Kondo T, Popivanova BK, Mukaida N. Crucial involvement of the CX3CR1-CX3CL1 axis in dextran sulfate sodium-mediated acute colitis in mice. J Leukoc Biol. 2010;88:133-143. [PMID: 20335311 DOI: 10.1189/jlb.1109768] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 58 |
Tursi A. Balsalazide in treating colonic diseases. Expert Opin Drug Metab Toxicol 2009;5:1555-63. [PMID: 19708827 DOI: 10.1517/17425250903228842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 59 |
Do VT, Baird BG, Kockler DR. Probiotics for maintaining remission of ulcerative colitis in adults. Ann Pharmacother. 2010;44:565-571. [PMID: 20124461 DOI: 10.1345/aph.1M498] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 60 |
Ogasawara N, Sasaki M, Hijikata Y, Masui R, Tanida S, Kanematsu T, Kamiya T, Kataoka H, Joh T, Kasugai K. Successful treatment for pouchitis with rebamipide refractory to a combination of metronidazole (MNZ) and ciprofloxacin (CFX). Clin J Gastroenterol 2009;2:404-7. [PMID: 26192795 DOI: 10.1007/s12328-009-0115-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 61 |
Fan H, Zhao J, Shen L, Tang Q, Shou Z, Liang L, Liao Y, Chen X. Effect of compound Sophorae Flavescentis Jiechangrong capsule on expression of NF-κB p65 and STAT6 in the intestinal mucosa of patients with ulcerative colitis. Front Med China 2009;3:480-4. [DOI: 10.1007/s11684-009-0083-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 62 |
Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, Shima C, Saniabadi AR, Matsumoto T. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009;41:570-7. [PMID: 19211314 DOI: 10.1016/j.dld.2008.11.020] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 63 |
Kruis W, Kiudelis G, Rácz I, Gorelov IA, Pokrotnieks J, Horynski M, Batovsky M, Kykal J, Boehm S, Greinwald R, Mueller R; International Salofalk OD Study Group. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009;58:233-40. [PMID: 18832520 DOI: 10.1136/gut.2008.154302] [Cited by in Crossref: 140] [Cited by in F6Publishing: 147] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 64 |
Terry PD, Villinger F, Bubenik GA, Sitaraman SV. Melatonin and ulcerative colitis: evidence, biological mechanisms, and future research. Inflamm Bowel Dis 2009;15:134-40. [PMID: 18626968 DOI: 10.1002/ibd.20527] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 65 |
Egan LJ. INFLAMMATION AND IMMUNOMODULATION. Pharmacology and Therapeutics 2009. [DOI: 10.1016/b978-1-4160-3291-5.50015-9] [Reference Citation Analysis]
|
| 66 |
Fedorak RN. Probiotics in Ulcerative Colitis. Probiotics in Pediatric Medicine 2009. [DOI: 10.1007/978-1-60327-289-6_13] [Reference Citation Analysis]
|
| 67 |
Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2008. [DOI: 10.1002/14651858.cd007443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 68 |
Ferrante M, Vermeire S, Fidder H, Schnitzler F, Noman M, Van Assche G, De Hertogh G, Hoffman I, D'Hoore A, Van Steen K, Geboes K, Penninckx F, Rutgeerts P. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008;2:219-25. [PMID: 21172214 DOI: 10.1016/j.crohns.2008.03.004] [Cited by in Crossref: 166] [Cited by in F6Publishing: 164] [Article Influence: 11.1] [Reference Citation Analysis]
|
| 69 |
Tursi A. Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon. J Clin Gastroenterol 2008;42 Suppl 3 Pt 1:S119-22. [PMID: 18806701 DOI: 10.1097/MCG.0b013e31815f5ac7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 70 |
Bailón E, Comalada M, Román J, Michelena P, Ramis I, Merlos M, Nieto A, Concha A, Zarzuelo A, Gálvez J. UR-1505, a salicylate able to selectively block T-cell activation, shows intestinal anti-inflammatory activity in the chronic phase of the DSS model of rat colitis. Inflamm Bowel Dis 2008;14:888-97. [PMID: 18253952 DOI: 10.1002/ibd.20381] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 71 |
Hanai H, Iida T, Takeuchi K, Watanabe F, Yamada M, Kikuyama M, Maruyama Y, Iwaoka Y, Hirayama K, Nagata S, Takai K. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol 2008;103:1210-6. [PMID: 18177452 DOI: 10.1111/j.1572-0241.2007.01714.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 72 |
Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C, Mukaida N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008;118:560-70. [PMID: 18219394 DOI: 10.1172/JCI32453] [Cited by in Crossref: 109] [Cited by in F6Publishing: 420] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 73 |
Shih TC, Hsieh SY, Hsieh YY, Chen TC, Yeh CY, Lin CJ, Lin DY, Chiu CT. Aberrant activation of nuclear factor of activated T cell 2 in lamina propria mononuclear cells in ulcerative colitis. World J Gastroenterol 2008; 14(11): 1759-1767 [PMID: 18350607 DOI: 10.3748/wjg.14.1759] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 74 |
Dundar E, Olgun EG, Isiksoy S, Kurkcuoglu M, Baser KH, Bal C. The effects of intra-rectal and intra-peritoneal application of Origanum onites L. essential oil on 2,4,6-trinitrobenzenesulfonic acid-induced colitis in the rat. Exp Toxicol Pathol 2008;59:399-408. [PMID: 18222658 DOI: 10.1016/j.etp.2007.11.009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 75 |
AETIOLOGY, PATHOLOGY AND MEDICAL ASPECTS OF ULCERATIVE COLITIS. Surgery of the Anus, Rectum & Colon 2008. [DOI: 10.1016/b978-0-7020-2723-9.50040-3] [Reference Citation Analysis]
|
| 76 |
Evans JA, Forcione DG, Friedman LS. Gastrointestinal Complications in the Postoperative Period. Medical Management of the Surgical Patient 2008. [DOI: 10.1016/b978-141602385-2.50010-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 77 |
Mack DR. Probiotic Therapy. Pediatric Inflammatory Bowel Disease. [DOI: 10.1007/978-0-387-73481-1_27] [Reference Citation Analysis]
|
| 78 |
Eliakim R, Tulassay Z, Kupcinskas L, Adamonis K, Pokrotnieks J, Bar-Meir S, Lavy A, Mueller R, Greinwald R, Chermesh I, Gross V; International Salofalk Foam Study Group. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. Aliment Pharmacol Ther 2007;26:1237-49. [PMID: 17944738 DOI: 10.1111/j.1365-2036.2007.03468.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 79 |
Bailón E, Camuesco D, Nieto A, Concha A, Arriba AFD, Román J, Ramis I, Merlos M, Zarzuelo A, Gálvez J, Comalada M. The intestinal anti-inflammatory effects of the novel agent UR-1505 in the TNBS model of rat colitis are mediated by T-lymphocyte inhibition. Biochemical Pharmacology 2007;74:1496-506. [DOI: 10.1016/j.bcp.2007.07.026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 80 |
Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Shima C, Bjarnason I, Lofberg R. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci. 2007;37:191-200. [PMID: 17974479 DOI: 10.1016/j.transci.2007.08.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 81 |
Pearce CB, Lawrance IC. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. J Gastroenterol Hepatol 2007;22:1671-7. [PMID: 17845695 DOI: 10.1111/j.1440-1746.2006.04739.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 82 |
Ghia JE, Blennerhassett P, Collins SM. Vagus nerve integrity and experimental colitis. Am J Physiol Gastrointest Liver Physiol 2007;293:G560-7. [PMID: 17585014 DOI: 10.1152/ajpgi.00098.2007] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 83 |
Emmrich J, Petermann S, Nowak D, Beutner I, Brock P, Klingel R, Mausfeld-Lafdhiya P, Liebe S, Ramlow W. Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis--results of a randomized pilot trial. Dig Dis Sci 2007;52:2044-53. [PMID: 17410456 DOI: 10.1007/s10620-006-9696-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 84 |
Lakatos L, Lakatos PL. [Medical therapy of inflammatory bowel diseases: ulcerative colitis]. Orv Hetil 2007;148:1163-70. [PMID: 17573252 DOI: 10.1556/OH.2007.28063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 85 |
Tilg H, Moschen A, Kaser A. Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases. Expert Opinion on Biological Therapy 2007;7:1051-9. [DOI: 10.1517/14712598.7.7.1051] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 86 |
Tilg H. Inflammatory bowel diseases: meeting of the European Crohn’s Colitis Organization: 1 – 3 March 2007, Innsbruck, Austria. Expert Opinion on Therapeutic Targets 2007;11:853-6. [DOI: 10.1517/14728222.11.6.853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 87 |
Ouyang Q, Zhang H, Wang Y, Chen X. Inflammatory bowel disease in Asia: response to therapy. Falk Symposium. [DOI: 10.1007/978-1-4020-5702-1_3] [Reference Citation Analysis]
|
| 88 |
Tursi A. New physiopathological and therapeutic approaches to diverticular disease of the colon. Expert Opin Pharmacother. 2007;8:299-307. [PMID: 17266465 DOI: 10.1517/14656566.8.3.299] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 89 |
Tersigni R, Alessandroni L, Bertolini R. Surgical Management of Acute Ulcerative Colitis. Inflammatory Bowel Disease and Familial Adenomatous Polyposis. [DOI: 10.1007/88-470-0434-9_25] [Reference Citation Analysis]
|
| 90 |
Thukral C, Cheifetz A, Peppercorn MA. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date. Drugs 2006;66:2059-65. [PMID: 17112300 DOI: 10.2165/00003495-200666160-00002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 91 |
Klotz U. Clinical impact of mesalazine for research and therapy in inflammatory bowel diseases. Falk Symposium. [DOI: 10.1007/1-4020-2916-0_29] [Reference Citation Analysis]
|
| 92 |
Neurath MF. Azathioprine: molecular mechanism of action. Falk Symposium. [DOI: 10.1007/1-4020-4316-3_15] [Reference Citation Analysis]
|
| 93 |
Ljung T, Thomsen OØ, Vatn M, Karlén P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Grip O, Lindgren S, Befrits R, Löfberg R. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007;42:221-7. [PMID: 17327942 DOI: 10.1080/00365520600979369] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 94 |
Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes JK, Rutgeerts P. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007;13:123-8. [PMID: 17206703 DOI: 10.1002/ibd.20054] [Cited by in Crossref: 131] [Cited by in F6Publishing: 98] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 95 |
Böcker U, Herold A, Kahl S. Kolon und Rektum. Interventionelle Endoskopie 2007. [DOI: 10.1016/b978-343723620-4.50012-9] [Reference Citation Analysis]
|
| 96 |
Kreiss CM, Bauer AJ. Ulcerative Colitis. xPharm: The Comprehensive Pharmacology Reference 2007. [DOI: 10.1016/b978-008055232-3.60799-8] [Reference Citation Analysis]
|
| 97 |
Pullen N, Gale J. Inflammatory Bowel Disease. Comprehensive Medicinal Chemistry II 2007. [DOI: 10.1016/b0-08-045044-x/00192-9] [Reference Citation Analysis]
|
| 98 |
Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577 [PMID: 17171783 DOI: 10.3748/wjg.v12.i47.7568] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 99 |
Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:1502-6. [PMID: 17101300 DOI: 10.1016/j.cgh.2006.08.008] [Cited by in Crossref: 406] [Cited by in F6Publishing: 469] [Article Influence: 23.9] [Reference Citation Analysis]
|
| 100 |
Ouyang Q, Tandon R, Goh KL, Pan GZ, Fock KM, Fiocchi C, Lam SK, Xiao SD. Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol 2006;21:1772-82. [PMID: 17074013 DOI: 10.1111/j.1440-1746.2006.04674.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 101 |
Lakatos L, Lakatos PL. Management of inflammatory bowel diseases in Eastern Europe. Postgrad Med J 2006;82:270-3. [PMID: 16597815 DOI: 10.1136/pgmj.2005.043901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 102 |
Bodegraven AAV, Mulder CJ. Indications for 5-aminosalicylate in inflammatory bowel disease: Is the body of evidence complete? World J Gastroenterol 2006; 12(38): 6115-6123 [PMID: 17036381 DOI: 10.3748/wjg.v12.i38.6115] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 103 |
Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, Ost A, Hittel N, Saniabadi A, Löfberg R. Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis 2006;21:493-504. [PMID: 16538495 DOI: 10.1007/s00384-005-0069-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 104 |
Lichtenstein GR, Cohen R, Yamashita B, Diamond RH. Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. J Clin Gastroenterol 2006;40:669-77. [PMID: 16940876 DOI: 10.1097/00004836-200609000-00002] [Cited by in Crossref: 68] [Cited by in F6Publishing: 51] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 105 |
Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006;23:1567-74. [PMID: 16696804 DOI: 10.1111/j.1365-2036.2006.02927.x] [Cited by in Crossref: 321] [Cited by in F6Publishing: 329] [Article Influence: 18.9] [Reference Citation Analysis]
|
| 106 |
Verdonk RC, Dijkstra G, Haagsma EB, Shostrom VK, Van den Berg AP, Kleibeuker JH, Langnas AN, Sudan DL. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant 2006;6:1422-9. [PMID: 16686766 DOI: 10.1111/j.1600-6143.2006.01333.x] [Cited by in Crossref: 124] [Cited by in F6Publishing: 116] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 107 |
Miner PB Jr, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther 2006;23:1403-13. [PMID: 16669955 DOI: 10.1111/j.1365-2036.2006.02837.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 108 |
Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol 2006;101:1048-56. [PMID: 16573777 DOI: 10.1111/j.1572-0241.2006.00524.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 127] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 109 |
Shindo K, Iizuka M, Sasaki K, Konno S, Itou H, Horie Y, Watanabe S. Sucralfate prevents the delay of wound repair in intestinal epithelial cells by hydrogen peroxide through NF-kappaB pathway. J Gastroenterol 2006;41:450-61. [PMID: 16799887 DOI: 10.1007/s00535-006-1787-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 110 |
Thukral C, Wolf JL. Therapy Insight: drugs for gastrointestinal disorders in pregnant women. Nat Rev Gastroenterol Hepatol 2006;3:256-66. [DOI: 10.1038/ncpgasthep0452] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 111 |
Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opinion on Biological Therapy 2006;6:453-66. [DOI: 10.1517/14712598.6.5.453] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 112 |
Tursi A. Mesalazine for diverticular disease of the colon--a new role for an old drug. Expert Opin Pharmacother. 2005;6:69-74. [PMID: 15709884 DOI: 10.1517/14656566.6.1.69] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 113 |
Ashizuka S, Nishiura R, Ishikawa N, Yamaga J, Inatsu H, Fujimoto S, Eto T. Leukocytapheresis for Ulcerative Colitis: A Comparative Study of Anticoagulant (Nafamostat Mesilate vs. Dalteparin Sodium) for Reducing Clinical Complications: LCAP for UC: Comparison of Anticoagulant. Therapeutic Apheresis and Dialysis 2006;10:54-8. [DOI: 10.1111/j.1744-9987.2006.00309.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 114 |
Masson S, Nylander D, Mansfield JC. How important is onset of action in ulcerative colitis therapy? Drugs. 2005;65:2069-2083. [PMID: 16225364 DOI: 10.2165/00003495-200565150-00001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 115 |
Miyata M, Konagaya T, Kakumu S, Mori T. Successful treatment of severe pouchitis with rebamipide refractory to antibiotics and corticosteroids: A case report. World J Gastroenterol 2006; 12(4): 656-658 [PMID: 16489687 DOI: 10.3748/wjg.v12.i4.656] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 116 |
D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J. 2006;20:568-570. [PMID: 16403786 DOI: 10.1096/fj.05-4943fje] [Cited by in Crossref: 165] [Cited by in F6Publishing: 175] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 117 |
Kiesslich R, Neurath MF. Detecting dysplasias in ulcerative colitis. Highlights in Gastrointestinal Oncology 2006. [DOI: 10.1007/1-4020-5223-5_11] [Reference Citation Analysis]
|
| 118 |
Okabe T, Ohya T, Sakamoto T, Matsumoto H, Kurabayashi M, Takahashi N, Iesato H, Yokomori T, Takeyoshi I, Ohwada S, Morishita Y. Severe Ulcerative Colitis Due to the Stress of an Earthquake Disaster-A Case Report-. Kitakanto Med J 2006;56:149-153. [DOI: 10.2974/kmj.56.149] [Reference Citation Analysis]
|
| 119 |
Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, Saito Y, Takeda Y, Umemura K, Kondo K, Ikeda Y, Fukunaga K, Nakashima M, Beretta A, Bjarnason I, Lofberg R. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher. 2005;20:171-184. [PMID: 15892107 DOI: 10.1002/jca.20046] [Cited by in Crossref: 78] [Cited by in F6Publishing: 86] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 120 |
Pham CQ, Efros CB, Berardi RR. Cyclosporine for severe ulcerative colitis. Ann Pharmacother 2006;40:96-101. [PMID: 16368919 DOI: 10.1345/aph.1G374] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 121 |
Singleton JW. Progress in inflammatory bowel disease. Chin J Dig Dis 2005;6:59-61. [PMID: 15904422 DOI: 10.1111/j.1443-9573.2005.00195.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 122 |
Klein S, Stein J, Dressman J. Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model. J Pharm Pharmacol 2005;57:709-19. [PMID: 15969925 DOI: 10.1211/0022357056172] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 123 |
Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Beclomethasone dipropionate plus VSL#3 for the treatment of mild to moderate diverticular colitis: an open, pilot study. J Clin Gastroenterol 2005;39:644-5. [PMID: 16000940 DOI: 10.1097/01.mcg.0000170741.82004.70] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 124 |
Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, Befrits R, Midhagen G, Rademaker J, Foldager M. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005;54:960-5. [PMID: 15951542 DOI: 10.1136/gut.2004.060103] [Cited by in Crossref: 247] [Cited by in F6Publishing: 257] [Article Influence: 13.7] [Reference Citation Analysis]
|
| 125 |
Ferraccioli G, Tomietto P, Santis M. Rationale for T Cell Inhibition by Cyclosporin A in Major Autoimmune Diseases. Annals of the New York Academy of Sciences 2005;1051:658-65. [DOI: 10.1196/annals.1361.110] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 126 |
Fefferman DS, Farrell RJ. Immunogenicity of biological agents in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:497-503. [PMID: 15867590 DOI: 10.1097/01.mib.0000161536.97412.41] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 127 |
Xin H, Fischer C, Schwab M, Klotz U. Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005;21:1105-9. [PMID: 15854172 DOI: 10.1111/j.1365-2036.2005.02460.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 128 |
Cheng Y, Desreumaux P. 5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. World J Gastroenterol 2005; 11(3): 309-314 [PMID: 15637733 DOI: 10.3748/wjg.v11.i3.309] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 45] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 129 |
Choi H, Choi KY. Diagnosis and Treatment of Ulcerative Colitis. J Korean Med Assoc 2005;48:154. [DOI: 10.5124/jkma.2005.48.2.154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 130 |
Raedler A, Behrens C, Bias P. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial. Aliment Pharmacol Ther 2004;20:1353-63. [PMID: 15606398 DOI: 10.1111/j.1365-2036.2004.02282.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
|
